Equities Analysts Issue Forecasts for VERA FY2029 Earnings

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Wedbush issued their FY2029 earnings per share (EPS) estimates for Vera Therapeutics in a research note issued to investors on Thursday, February 27th. Wedbush analyst L. Chico anticipates that the company will post earnings per share of $2.16 for the year. Wedbush has a "Neutral" rating and a $38.00 price objective on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share. Wedbush also issued estimates for Vera Therapeutics' FY2029 earnings at $2.16 EPS.

VERA has been the subject of several other reports. JPMorgan Chase & Co. lifted their price target on Vera Therapeutics from $72.00 to $75.00 and gave the company an "overweight" rating in a research report on Tuesday, November 5th. The Goldman Sachs Group assumed coverage on Vera Therapeutics in a research report on Tuesday, January 28th. They issued a "buy" rating and a $58.00 price target for the company. Guggenheim lifted their price target on Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research report on Thursday. Wolfe Research assumed coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price target for the company. Finally, Wells Fargo & Company assumed coverage on Vera Therapeutics in a research report on Thursday, November 21st. They issued an "overweight" rating and a $70.00 price target for the company. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Vera Therapeutics currently has a consensus rating of "Buy" and an average price target of $65.11.

Vera Therapeutics Stock Performance

NASDAQ:VERA traded down $1.52 during trading hours on Friday, reaching $28.41. The stock had a trading volume of 789,778 shares, compared to its average volume of 905,249. The stock has a market cap of $1.80 billion, a P/E ratio of -10.89 and a beta of 1.11. Vera Therapeutics has a 12-month low of $25.99 and a 12-month high of $51.61. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The stock has a 50 day simple moving average of $35.47 and a 200 day simple moving average of $40.28.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.83) by $0.11.

Institutional Investors Weigh In On Vera Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Huntington National Bank bought a new stake in Vera Therapeutics during the fourth quarter worth about $26,000. AlphaQuest LLC bought a new stake in Vera Therapeutics during the fourth quarter worth about $34,000. GF Fund Management CO. LTD. bought a new stake in Vera Therapeutics during the fourth quarter worth about $56,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Vera Therapeutics by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company's stock worth $86,000 after purchasing an additional 350 shares during the last quarter. Finally, KBC Group NV lifted its stake in Vera Therapeutics by 127.2% during the fourth quarter. KBC Group NV now owns 2,477 shares of the company's stock worth $105,000 after purchasing an additional 1,387 shares during the last quarter. Institutional investors own 99.21% of the company's stock.

Insider Activity at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $43.07, for a total transaction of $753,725.00. Following the completion of the sale, the chief executive officer now owns 85,942 shares of the company's stock, valued at $3,701,521.94. The trade was a 16.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last quarter, insiders sold 52,500 shares of company stock valued at $2,305,625. Company insiders own 21.70% of the company's stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.